Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction on Friday, November 13th. The stock was sold at an average price of $72.67, for a total value of $726,700.00. Following the completion of the sale, the director owned 1,044,543 shares of the company's stock, valued at $75,906,939.81. This represents a 0.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Corcept Therapeutics Trading Up 1.2%
Shares of CORT traded up $0.85 during midday trading on Tuesday, reaching $70.07. 985,538 shares of the stock were exchanged, compared to its average volume of 1,465,897. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $126.38. The company's 50 day moving average is $102.85 and its two-hundred day moving average is $76.55. The company has a market capitalization of $7.67 billion, a P/E ratio of 55.17 and a beta of 0.54.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The firm had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. During the same period in the previous year, the company posted $0.16 earnings per share. The firm's quarterly revenue was up 64.0% on a year-over-year basis. On average, sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.97 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on CORT shares. Wall Street Zen upgraded shares of Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 1st. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. Wolfe Research downgraded shares of Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. Weiss Ratings raised shares of Corcept Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, November 4th. Finally, Truist Financial initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a "buy" rating and a $164.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $139.50.
View Our Latest Research Report on Corcept Therapeutics
Hedge Funds Weigh In On Corcept Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Aquatic Capital Management LLC purchased a new position in Corcept Therapeutics during the 3rd quarter worth $3,975,000. State of Tennessee Department of Treasury raised its stake in Corcept Therapeutics by 21.4% in the third quarter. State of Tennessee Department of Treasury now owns 44,425 shares of the biotechnology company's stock valued at $5,119,000 after buying an additional 7,824 shares during the last quarter. Jump Financial LLC purchased a new stake in Corcept Therapeutics in the third quarter valued at about $973,000. FORA Capital LLC purchased a new stake in Corcept Therapeutics in the third quarter valued at about $1,166,000. Finally, EP Wealth Advisors LLC boosted its holdings in Corcept Therapeutics by 5.9% in the third quarter. EP Wealth Advisors LLC now owns 5,136 shares of the biotechnology company's stock worth $592,000 after acquiring an additional 286 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body's response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corcept Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.
While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.